Press release
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight
Focal Segmental Glomerulosclerosis (FSGS) Market
(Albany, USA) DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Focal Segmental Glomerulosclerosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted FSGS market size from 2020 to 2034, segmented by seven major markets. The Focal Segmental Glomerulosclerosis Market Report also covers current FSGS treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Focal Segmental Glomerulosclerosis market.
To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market Forecast [https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report:
* The Focal Segmental Glomerulosclerosis market size was valued approximately USD 734 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In 2022, the US accounted for approximately 34% of the total FSGS market, with projections indicating a significant compound annual growth rate (CAGR) during the study period.
* In 2022, the EU4 countries and the UK generated an estimated USD 147 million, with this figure expected to grow at a significant CAGR. Among the European nations, France held the largest market share in 2022, followed by Germany.
* According to DelveInsight's assessments, there were roughly 55 million diagnosed prevalent cases of FSGS in the 7MM in 2022, with expectations of a rise during the forecast period.
* In 2022, around 26 million individuals in the United States were diagnosed with FSGS, and this number is projected to rise at an estimated CAGR throughout the study period from 2020 to 2034.
* In EU4 and the UK, Germany had the largest diagnosed prevalent population of FSGS in 2022, with approximately 5 million cases, followed by France and Italy. Conversely, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
* Key Focal Segmental Glomerulosclerosis Companies: Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
* Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
* The Focal Segmental Glomerulosclerosis epidemiology based on gender analyzed that Focal Segmental Glomerulosclerosis is more prevalent in males than females in the United States
* The Focal Segmental Glomerulosclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Focal Segmental Glomerulosclerosis pipeline products will significantly revolutionize the Focal Segmental Glomerulosclerosis market dynamics.
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a progressive kidney disease characterized by scarring (sclerosis) in segments of some glomeruli, the filtering units of the kidney. It is a leading cause of nephrotic syndrome and can result in chronic kidney disease (CKD) or end-stage renal disease (ESRD). FSGS can be classified as primary (idiopathic) or secondary, with causes including genetic mutations, infections, drug toxicity, obesity, and adaptive responses to kidney injury.
Patients with FSGS often present with proteinuria, edema, hypertension, and declining kidney function. Diagnosis is confirmed through kidney biopsy, which shows segmental sclerosis in affected glomeruli. Additional tests, including serum creatinine, estimated glomerular filtration rate (eGFR), and proteinuria levels, help assess disease severity.
Focal Segmental Glomerulosclerosis Treatment aims to reduce proteinuria, control blood pressure, and slow disease progression. Corticosteroids and immunosuppressants are first-line therapies for primary FSGS, while secondary FSGS is managed by addressing the underlying cause. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) help reduce proteinuria and protect kidney function. In severe cases, dialysis or kidney transplantation may be required.
Early Focal Segmental Glomerulosclerosis diagnosis and tailored treatment are crucial for improving outcomes and delaying kidney function decline in FSGS patients.
Get a Free sample for the Focal Segmental Glomerulosclerosis Market Report: Focal Segmental Glomerulosclerosis Market Size [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Focal Segmental Glomerulosclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Focal Segmental Glomerulosclerosis Epidemiology Segmentation:
The Focal Segmental Glomerulosclerosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
* Total Prevalence of Focal Segmental Glomerulosclerosis
* Prevalent Cases of Focal Segmental Glomerulosclerosis by severity
* Gender-specific Prevalence of Focal Segmental Glomerulosclerosis
* Diagnosed Cases of Episodic and Chronic Focal Segmental Glomerulosclerosis
Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis epidemiology trends @ Focal Segmental Glomerulosclerosis Epidemiology Forecast [https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Focal Segmental Glomerulosclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Focal Segmental Glomerulosclerosis market or expected to get launched during the study period. The analysis covers Focal Segmental Glomerulosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Focal Segmental Glomerulosclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Focal Segmental Glomerulosclerosis Therapies and Key Companies
* Sparsentan: Travere Therapeutics
* DMX-200: Dimerix
* GFB-887: Goldfinch Bio
* VX-147: Vertex Pharmaceuticals
* Losmapimod: GlaxoSmithKline
* Propagermanium: Dimerix Bioscience Pty Ltd
* RE-021 (Sparsentan): Travere Therapeutics, Inc.
* CCX140-B: ChemoCentryx
* Dapagliflozin: AstraZeneca
* rituximab: Genentech, Inc.
* fresolimumab: Sanofi
* Acthar Gel: Mallinckrodt ARD LLC
* VB119: ACELYRIN Inc.
* Bleselumab: Kyowa Kirin Co., Ltd.
* Abatacept: Bristol-Myers Squibb
Request for sample report @ Focal Segmental Glomerulosclerosis Drugs Market [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Focal Segmental Glomerulosclerosis Market Strengths
The frequency of Focal Segmental Glomerulosclerosis appears to be increasing worldwide, which presents a promising opportunity for various companies to develop novel therapies
The advent of next-generation sequencing promises to provide nephrologists with rapid and novel approaches for diagnosing and treating Focal Segmental Glomerulosclerosis
A stratified and targeted approach is being evolved based on the underlying molecular defects
Focal Segmental Glomerulosclerosis Market Unmet Needs
* Heterogeneity in the disease presentation
* The requirement for cutting-edge diagnosis
* Restricted specific epidemiological studies
* Inadequate therapeutic options
Scope of the Focal Segmental Glomerulosclerosis Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Focal Segmental Glomerulosclerosis Companies: Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
* Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
* Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
* Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Focal Segmental Glomerulosclerosis Unmet Needs, KOL's views, Analyst's views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement
To know more about Focal Segmental Glomerulosclerosis companies working in the treatment market, visit @ Focal Segmental Glomerulosclerosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Focal Segmental Glomerulosclerosis Market Report Introduction
2. Executive Summary for Focal Segmental Glomerulosclerosis
3. SWOT analysis of Focal Segmental Glomerulosclerosis
4. Focal Segmental Glomerulosclerosis Patient Share (%) Overview at a Glance
5. Focal Segmental Glomerulosclerosis Market Overview at a Glance
6. Focal Segmental Glomerulosclerosis Disease Background and Overview
7. Focal Segmental Glomerulosclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Focal Segmental Glomerulosclerosis
9. Focal Segmental Glomerulosclerosis Current Treatment and Medical Practices
10. Focal Segmental Glomerulosclerosis Unmet Needs
11. Focal Segmental Glomerulosclerosis Emerging Therapies
12. Focal Segmental Glomerulosclerosis Market Outlook
13. Country-Wise Focal Segmental Glomerulosclerosis Market Analysis (2020-2034)
14. Focal Segmental Glomerulosclerosis Market Access and Reimbursement of Therapies
15. Focal Segmental Glomerulosclerosis Market Drivers
16. Focal Segmental Glomerulosclerosis Market Barriers
17. Focal Segmental Glomerulosclerosis Appendix
18. Focal Segmental Glomerulosclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-fsgs-treatment-market-2034-clinical-trials-ema-pdma-fda-approvals-medication-patient-pool-moa-roa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight here
News-ID: 3862732 • Views: …
More Releases from ABNewswire
Chemotherapy Induced Anemia Drugs Market 2032: Clinical Trials, Medication, Prev …
Chemotherapy Induced Anemia companies are Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5…
Bone Metastasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals …
Bone Metastasis companies are Amgen, Actuate Therapeutics, Exelixi, QSAM Biosciences Inc., Daiichi Sankyo Inc, Pfizer, Eli Lilly and Company, Novartis, Bayer, and Many Others.
(Albany, USA) DelveInsight's "Bone Metastasis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Bone Metastasis, historical and forecasted epidemiology as well as the Bone Metastasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Bone Metastasis…
Cutaneous T-Cell Lymphoma (CTCL) Treatment Market 2034: Clinical Trials, Medicat …
CTCL Companies are Citius Pharmaceuticals, Codiak BioSciences, Elorac, Equillium, Genzada Pharmaceuticals, Hoffmann-La Roche, Innate Pharma, Jiangsu Simcere Pharmaceutical, Kymera Therapeutics, Legend Biotech, 4SC, Bio-Path Holdings, BioInvent International AB, Bioniz Therapeutics, Merck Sharp & Dohme LLC, miRagen Therapeutics, Myeloid Therapeutics, Otsuka Pharmaceutical, Scopus BioPharma, Soligenix, Sorrento Therapeutics, VidacPharma, Viridian Therapeutics, and many others.
(Albany, USA) DelveInsight's "Cutaneous T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Cutaneous…
B-Cell Lymphomas Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approval …
B-Cell Lymphomas companies are Pfizer, Xynomic Pharmaceuticals, Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Merck Sharp & Dohme, Sanofi, InnoCare Pharma, Allogene Therapeutics, Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical, Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Antengene Corp, more.
(Albany, USA) DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth…
More Releases for Focal
Subwoofers Market Disclosing Latest Advancement 2021 to 2027 | Dual, Focal
This Subwoofers market report breaks down the market into segments and sub-segments. With this market analysis, managing the outline of the industries gets simple. This Subwoofers market report also assists in making informed decisions by giving unique industry insights as well as historical and projected industry data. It presents a worldwide market scenario to assist important companies in establishing themselves and surviving in the market. This Subwoofers market report analysis…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Innovation becomes the focal point in the 3D technology industry
3D technology is one of the enigmatic marvels of the world. It is difficult to determine how it will change the world and bring innovative ways to save cost and improve efficiency. Innovation has become the heart of advancements in the 3D technology sector. A Liverpool-based startup has begun production of customizable eco-coffins using 3D printing technology. A leading market player has launched a unique dot forming AM technology that…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
